Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amneal pharmaceuticals inc - AMRX

AMRX

Close Chg Chg %
17.27 0.05 0.29%

Closed Market

17.32

+0.05 (0.29%)

Volume: 2.42M

Last Updated:

Jun 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: amneal pharmaceuticals inc - AMRX

AMRX Key Data

Open

$17.39

 Day Range

17.21 - 17.78

52 Week Range

7.67 - 17.40

 Market Cap

$5.51B

Shares Outstanding

319.02M

 Public Float

156.03M

Beta

1.30

 Rev. Per Employee

N/A

P/E Ratio

46.30

 EPS

$0.39

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.03M

  

AMRX Performance

1 Week
 
 6.54%
 
1 Month
 
 39.05%
 
3 Months
 
 45.74%
 
1 Year
 
 112.42%
 
5 Years
 
 223.41%
 

AMRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About amneal pharmaceuticals inc - AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX At a Glance

Amneal Pharmaceuticals, Inc.
400 Crossing Boulevard
Bridgewater, New Jersey 08807
Phone 1-908-947-3120 Revenue 3.02B
Industry Pharmaceuticals: Major Net Income 72.06M
Sector Health Technology 2025 Sales Growth 8.046%
Fiscal Year-end 12 / 2026 Employees 8,500
View SEC Filings

AMRX Valuation

P/E Current 44.665
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 56.808
Price to Sales Ratio 1.356
Price to Book Ratio N/A
Price to Cash Flow Ratio 12.04
Enterprise Value to EBITDA 10.125
Enterprise Value to Sales 2.169
Total Debt to Enterprise Value 0.411

AMRX Efficiency

Revenue/Employee 355,148.235
Income Per Employee 8,477.294
Receivables Turnover 3.212
Total Asset Turnover 0.841

AMRX Liquidity

Current Ratio 2.168
Quick Ratio 1.48
Cash Ratio 0.353

AMRX Profitability

Gross Margin 37.634
Operating Margin 14.015
Pretax Margin 4.611
Net Margin 2.387
Return on Assets 2.007
Return on Equity N/A
Return on Total Capital 2.752
Return on Invested Capital 3.04

AMRX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 102.704
Total Debt to Total Assets 73.106
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 101.88
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amneal Pharmaceuticals Inc - AMRX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.21B 2.39B 2.79B 3.02B
Sales Growth
+5.67% +8.20% +16.73% +8.05%
Cost of Goods Sold (COGS) incl D&A
1.42B 1.54B 1.77B 1.88B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
240.18M 229.40M 236.19M 223.57M
Depreciation
68.11M 66.20M 62.60M 57.30M
Amortization of Intangibles
172.06M 163.20M 173.59M 166.27M
COGS Growth
+8.79% +8.50% +15.39% +6.15%
Gross Income
795.82M 856.66M 1.02B 1.14B
Gross Income Growth
+0.52% +7.65% +19.12% +11.33%
Gross Profit Margin
+35.97% +35.79% +36.52% +37.63%
2022 2023 2024 2025 5-year trend
SG&A Expense
595.39M 593.63M 667.15M 713.00M
Research & Development
195.69M 163.95M 190.71M 186.18M
Other SG&A
399.70M 429.68M 476.44M 526.83M
SGA Growth
+4.94% -0.30% +12.39% +6.87%
Other Operating Expense
- - - -
-
Unusual Expense
299.61M 100.61M 103.96M 65.60M
EBIT after Unusual Expense
(99.18M) 162.43M 249.33M 357.49M
Non Operating Income/Expense
9.43M 7.93M (45.74M) 22.81M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
158.38M 210.63M 258.60M 241.09M
Interest Expense Growth
+16.18% +32.99% +22.77% -6.77%
Gross Interest Expense
158.38M 210.63M 258.60M 241.09M
Interest Capitalized
- - - -
-
Pretax Income
(248.13M) (40.27M) (55.01M) 139.21M
Pretax Income Growth
-891.07% +83.77% -36.61% +353.05%
Pretax Margin
-11.22% -1.68% -1.97% +4.61%
Income Tax
6.66M 8.45M 18.86M 11.28M
Income Tax - Current - Domestic
(1.07M) 2.47M 8.31M (186.00K)
Income Tax - Current - Foreign
7.74M 5.98M 10.55M 11.46M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(254.79M) (48.72M) (73.88M) 127.93M
Minority Interest Expense
(124.80M) 35.27M 43.01M 55.88M
Net Income
(129.99M) (83.99M) (116.89M) 72.06M
Net Income Growth
-1,323.51% +35.38% -39.16% +161.65%
Net Margin Growth
-5.88% -3.51% -4.18% +2.39%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(129.99M) (83.99M) (116.89M) 72.06M
Preferred Dividends
- - - -
-
Net Income Available to Common
(129.99M) (83.99M) (116.89M) 72.06M
EPS (Basic)
-0.8612 -0.4769 -0.3783 0.2299
EPS (Basic) Growth
-1,307.85% +44.62% +20.68% +160.77%
Basic Shares Outstanding
150.94M 176.14M 308.98M 313.37M
EPS (Diluted)
-0.8612 -0.4769 -0.3783 0.2218
EPS (Diluted) Growth
-1,330.29% +44.62% +20.68% +158.63%
Diluted Shares Outstanding
150.94M 176.14M 308.98M 324.81M
EBITDA
440.61M 492.44M 589.48M 646.66M
EBITDA Growth
-3.74% +11.76% +19.71% +9.70%
EBITDA Margin
+19.92% +20.57% +21.10% +21.42%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 17.20
Number of Ratings 5 Current Quarters Estimate 0.225
FY Report Date 06 / 2026 Current Year's Estimate 0.982
Last Quarter’s Earnings 0.27 Median PE on CY Estimate N/A
Year Ago Earnings 0.83 Next Fiscal Year Estimate 1.126
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate 0.22 0.24 0.98 1.13
High Estimates 0.25 0.25 1.00 1.20
Low Estimate 0.21 0.22 0.94 1.04
Coefficient of Variance 7.61 6.38 2.93 5.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 4 4
OVERWEIGHT 1 1 1
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Amneal Pharmaceuticals Inc - AMRX

Date Name Shares Transaction Value
May 12, 2026 Deborah M. Autor Director 128,479 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 J. Kevin Buchi Director 19,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 J. Kevin Buchi Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 J. Kevin Buchi Director 75,077 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Ted C. Nark Director 19,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 Ted C. Nark Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Ted C. Nark Director 325,848 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Paul M. Meister Director 832,800 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Jeffrey P. George Director 19,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 Gautam Patel Director 1,643,963 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Shlomo Yanai Director 320,804 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Paul M. Meister Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Shlomo Yanai Director 19,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 Jeffrey P. George Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Paul M. Meister Director 30,837 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 Deborah M. Autor Director 19,824 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 12, 2026 Gautam Patel Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Shlomo Yanai Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Jeffrey P. George Director 344,614 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 12, 2026 Deborah M. Autor Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Amneal Pharmaceuticals Inc in the News